FY2027 Earnings Forecast for Merus Issued By Leerink Partnrs

Merus (NASDAQ:MRUS - Free Report) - Leerink Partnrs dropped their FY2027 earnings estimates for Merus in a research note issued to investors on Monday, April 28th. Leerink Partnrs analyst A. Berens now anticipates that the biotechnology company will post earnings of $3.99 per share for the year, down from their prior estimate of $4.01. The consensus estimate for Merus' current full-year earnings is ($3.85) per share.

Merus (NASDAQ:MRUS - Get Free Report) last posted its earnings results on Thursday, February 27th. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.89) by $0.48. The firm had revenue of $9.14 million for the quarter, compared to analyst estimates of $10.57 million. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%.

Other research analysts have also issued reports about the stock. Piper Sandler assumed coverage on shares of Merus in a report on Thursday, February 13th. They issued an "overweight" rating and a $84.00 target price on the stock. Bank of America dropped their price target on Merus from $73.00 to $70.00 and set a "buy" rating for the company in a research note on Monday, March 10th. Needham & Company LLC reissued a "buy" rating and issued a $83.00 price objective on shares of Merus in a research report on Wednesday, April 9th. Wells Fargo & Company initiated coverage on Merus in a report on Friday, February 7th. They issued an "overweight" rating and a $91.00 price target for the company. Finally, William Blair restated an "outperform" rating on shares of Merus in a report on Monday, April 28th. One research analyst has rated the stock with a sell rating, fourteen have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Merus presently has an average rating of "Buy" and an average target price of $85.31.

Merus Trading Down 1.1 %

Shares of NASDAQ:MRUS traded down $0.49 on Wednesday, hitting $43.70. The company had a trading volume of 102,477 shares, compared to its average volume of 709,688. The company has a market cap of $3.02 billion, a PE ratio of -11.08 and a beta of 0.94. The business has a 50 day moving average of $43.96 and a 200 day moving average of $44.43. Merus has a 52-week low of $33.19 and a 52-week high of $61.61.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of MRUS. Boxer Capital Management LLC acquired a new stake in shares of Merus in the fourth quarter valued at $79,895,000. Avoro Capital Advisors LLC increased its holdings in shares of Merus by 56.8% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,125,000 shares of the biotechnology company's stock valued at $89,356,000 after buying an additional 770,000 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Merus by 21.1% during the 4th quarter. Wellington Management Group LLP now owns 3,497,653 shares of the biotechnology company's stock valued at $147,076,000 after acquiring an additional 610,139 shares during the last quarter. Gilead Sciences Inc. bought a new stake in shares of Merus during the 4th quarter worth $19,029,000. Finally, Polar Capital Holdings Plc grew its holdings in shares of Merus by 34.7% in the 4th quarter. Polar Capital Holdings Plc now owns 1,706,238 shares of the biotechnology company's stock worth $71,747,000 after acquiring an additional 439,186 shares during the last quarter. Institutional investors own 96.14% of the company's stock.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.